Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Refractory multisystem sarcoidosis responding to infliximab therapy

Identifieur interne : 001F35 ( Istex/Corpus ); précédent : 001F34; suivant : 001F36

Refractory multisystem sarcoidosis responding to infliximab therapy

Auteurs : Adam P. Croft ; Deva Situnayake ; Omer Khair ; Gavin Giovanni ; David Carruthers ; Arul Sivaguru ; Caroline Gordon

Source :

RBID : ISTEX:4303396DF0D0F3299EE4D5B86D8FEDA5DB53C7F9

English descriptors

Abstract

Abstract: Chronic progressive multisystem granulomatous disease is seen in 10–30% of patients with sarcoidosis and can result in end organ damage. Corticosteroids are the mainstay of treatment with the addition of cytotoxic agents in severe cases. Some patients are refractory to such treatment and, therefore, management is a challenge. There is currently limited evidence for biological agents such as infliximab, a monoclonal anti-tumor necrosis factor-α antibody in the treatment of multisystem sarcoidosis. We report outcomes of three patients with extensive multisystem sarcoidosis refractory to conventional treatment and treated at our center. Clinical assessment and radiographic imaging were used to assess the response to infliximab treatment. Infliximab therapy induced clinical remission in all three patients, and this clinical response correlated with radiographic evidence of the resolution of granulomatous disease. Serum ACE level was reduced in all cases, and daily steroid dosage was reduced. We propose that infliximab can be an effective treatment in patients with multisystem complex sarcoidosis refractory to conventional drug therapy and can result in sustained clinical remission. Our experience supports the urgent need for randomized controlled clinical trials of anti-TNF therapy in refractory systemic sarcoidosis.

Url:
DOI: 10.1007/s10067-011-1933-9

Links to Exploration step

ISTEX:4303396DF0D0F3299EE4D5B86D8FEDA5DB53C7F9

Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Refractory multisystem sarcoidosis responding to infliximab therapy</title>
<author>
<name sortKey="Croft, Adam P" sort="Croft, Adam P" uniqKey="Croft A" first="Adam P." last="Croft">Adam P. Croft</name>
<affiliation>
<mods:affiliation>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>School of Infection and Immunity, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, B15 2TT, Birmingham, UK</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Situnayake, Deva" sort="Situnayake, Deva" uniqKey="Situnayake D" first="Deva" last="Situnayake">Deva Situnayake</name>
<affiliation>
<mods:affiliation>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Khair, Omer" sort="Khair, Omer" uniqKey="Khair O" first="Omer" last="Khair">Omer Khair</name>
<affiliation>
<mods:affiliation>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Giovanni, Gavin" sort="Giovanni, Gavin" uniqKey="Giovanni G" first="Gavin" last="Giovanni">Gavin Giovanni</name>
<affiliation>
<mods:affiliation>Queen Mary University of London, Centre for Neuroscience and Trauma, Blizard Institute, Barts and The London School of Medicine and Dentistry, 4 Newark Street, E1 2AT, London, UK</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Carruthers, David" sort="Carruthers, David" uniqKey="Carruthers D" first="David" last="Carruthers">David Carruthers</name>
<affiliation>
<mods:affiliation>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Sivaguru, Arul" sort="Sivaguru, Arul" uniqKey="Sivaguru A" first="Arul" last="Sivaguru">Arul Sivaguru</name>
<affiliation>
<mods:affiliation>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Gordon, Caroline" sort="Gordon, Caroline" uniqKey="Gordon C" first="Caroline" last="Gordon">Caroline Gordon</name>
<affiliation>
<mods:affiliation>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>School of Infection and Immunity, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, B15 2TT, Birmingham, UK</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>E-mail: p.c.gordon@bham.ac.uk</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:4303396DF0D0F3299EE4D5B86D8FEDA5DB53C7F9</idno>
<date when="2012" year="2012">2012</date>
<idno type="doi">10.1007/s10067-011-1933-9</idno>
<idno type="url">https://api.istex.fr/ark:/67375/VQC-XQPFMTGL-4/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001F35</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001F35</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Refractory multisystem sarcoidosis responding to infliximab therapy</title>
<author>
<name sortKey="Croft, Adam P" sort="Croft, Adam P" uniqKey="Croft A" first="Adam P." last="Croft">Adam P. Croft</name>
<affiliation>
<mods:affiliation>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>School of Infection and Immunity, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, B15 2TT, Birmingham, UK</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Situnayake, Deva" sort="Situnayake, Deva" uniqKey="Situnayake D" first="Deva" last="Situnayake">Deva Situnayake</name>
<affiliation>
<mods:affiliation>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Khair, Omer" sort="Khair, Omer" uniqKey="Khair O" first="Omer" last="Khair">Omer Khair</name>
<affiliation>
<mods:affiliation>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Giovanni, Gavin" sort="Giovanni, Gavin" uniqKey="Giovanni G" first="Gavin" last="Giovanni">Gavin Giovanni</name>
<affiliation>
<mods:affiliation>Queen Mary University of London, Centre for Neuroscience and Trauma, Blizard Institute, Barts and The London School of Medicine and Dentistry, 4 Newark Street, E1 2AT, London, UK</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Carruthers, David" sort="Carruthers, David" uniqKey="Carruthers D" first="David" last="Carruthers">David Carruthers</name>
<affiliation>
<mods:affiliation>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Sivaguru, Arul" sort="Sivaguru, Arul" uniqKey="Sivaguru A" first="Arul" last="Sivaguru">Arul Sivaguru</name>
<affiliation>
<mods:affiliation>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Gordon, Caroline" sort="Gordon, Caroline" uniqKey="Gordon C" first="Caroline" last="Gordon">Caroline Gordon</name>
<affiliation>
<mods:affiliation>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>School of Infection and Immunity, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, B15 2TT, Birmingham, UK</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>E-mail: p.c.gordon@bham.ac.uk</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Clinical Rheumatology</title>
<title level="j" type="sub">Journal of the International League of Associations for Rheumatology</title>
<title level="j" type="abbrev">Clin Rheumatol</title>
<idno type="ISSN">0770-3198</idno>
<idno type="eISSN">1434-9949</idno>
<imprint>
<publisher>Springer-Verlag</publisher>
<pubPlace>London</pubPlace>
<date type="published" when="2012-06-01">2012-06-01</date>
<biblScope unit="volume">31</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="1013">1013</biblScope>
<biblScope unit="page" to="1018">1018</biblScope>
</imprint>
<idno type="ISSN">0770-3198</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0770-3198</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Anti-TNF</term>
<term>Infliximab</term>
<term>Neurosarcoidosis</term>
<term>Refractory</term>
<term>Sarcoidosis</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Abstract: Chronic progressive multisystem granulomatous disease is seen in 10–30% of patients with sarcoidosis and can result in end organ damage. Corticosteroids are the mainstay of treatment with the addition of cytotoxic agents in severe cases. Some patients are refractory to such treatment and, therefore, management is a challenge. There is currently limited evidence for biological agents such as infliximab, a monoclonal anti-tumor necrosis factor-α antibody in the treatment of multisystem sarcoidosis. We report outcomes of three patients with extensive multisystem sarcoidosis refractory to conventional treatment and treated at our center. Clinical assessment and radiographic imaging were used to assess the response to infliximab treatment. Infliximab therapy induced clinical remission in all three patients, and this clinical response correlated with radiographic evidence of the resolution of granulomatous disease. Serum ACE level was reduced in all cases, and daily steroid dosage was reduced. We propose that infliximab can be an effective treatment in patients with multisystem complex sarcoidosis refractory to conventional drug therapy and can result in sustained clinical remission. Our experience supports the urgent need for randomized controlled clinical trials of anti-TNF therapy in refractory systemic sarcoidosis.</div>
</front>
</TEI>
<istex>
<corpusName>springer-journals</corpusName>
<author>
<json:item>
<name>Adam P. Croft</name>
<affiliations>
<json:string>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</json:string>
<json:string>School of Infection and Immunity, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, B15 2TT, Birmingham, UK</json:string>
</affiliations>
</json:item>
<json:item>
<name>Deva Situnayake</name>
<affiliations>
<json:string>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</json:string>
</affiliations>
</json:item>
<json:item>
<name>Omer Khair</name>
<affiliations>
<json:string>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</json:string>
</affiliations>
</json:item>
<json:item>
<name>Gavin Giovanni</name>
<affiliations>
<json:string>Queen Mary University of London, Centre for Neuroscience and Trauma, Blizard Institute, Barts and The London School of Medicine and Dentistry, 4 Newark Street, E1 2AT, London, UK</json:string>
</affiliations>
</json:item>
<json:item>
<name>David Carruthers</name>
<affiliations>
<json:string>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</json:string>
</affiliations>
</json:item>
<json:item>
<name>Arul Sivaguru</name>
<affiliations>
<json:string>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</json:string>
</affiliations>
</json:item>
<json:item>
<name>Caroline Gordon</name>
<affiliations>
<json:string>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</json:string>
<json:string>School of Infection and Immunity, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, B15 2TT, Birmingham, UK</json:string>
<json:string>E-mail: p.c.gordon@bham.ac.uk</json:string>
</affiliations>
</json:item>
</author>
<subject>
<json:item>
<lang>
<json:string>eng</json:string>
</lang>
<value>Anti-TNF</value>
</json:item>
<json:item>
<lang>
<json:string>eng</json:string>
</lang>
<value>Infliximab</value>
</json:item>
<json:item>
<lang>
<json:string>eng</json:string>
</lang>
<value>Neurosarcoidosis</value>
</json:item>
<json:item>
<lang>
<json:string>eng</json:string>
</lang>
<value>Refractory</value>
</json:item>
<json:item>
<lang>
<json:string>eng</json:string>
</lang>
<value>Sarcoidosis</value>
</json:item>
</subject>
<articleId>
<json:string>1933</json:string>
<json:string>s10067-011-1933-9</json:string>
</articleId>
<arkIstex>ark:/67375/VQC-XQPFMTGL-4</arkIstex>
<language>
<json:string>eng</json:string>
</language>
<originalGenre>
<json:string>ReviewPaper</json:string>
</originalGenre>
<abstract>Abstract: Chronic progressive multisystem granulomatous disease is seen in 10–30% of patients with sarcoidosis and can result in end organ damage. Corticosteroids are the mainstay of treatment with the addition of cytotoxic agents in severe cases. Some patients are refractory to such treatment and, therefore, management is a challenge. There is currently limited evidence for biological agents such as infliximab, a monoclonal anti-tumor necrosis factor-α antibody in the treatment of multisystem sarcoidosis. We report outcomes of three patients with extensive multisystem sarcoidosis refractory to conventional treatment and treated at our center. Clinical assessment and radiographic imaging were used to assess the response to infliximab treatment. Infliximab therapy induced clinical remission in all three patients, and this clinical response correlated with radiographic evidence of the resolution of granulomatous disease. Serum ACE level was reduced in all cases, and daily steroid dosage was reduced. We propose that infliximab can be an effective treatment in patients with multisystem complex sarcoidosis refractory to conventional drug therapy and can result in sustained clinical remission. Our experience supports the urgent need for randomized controlled clinical trials of anti-TNF therapy in refractory systemic sarcoidosis.</abstract>
<qualityIndicators>
<score>7.167</score>
<pdfWordCount>2923</pdfWordCount>
<pdfCharCount>19808</pdfCharCount>
<pdfVersion>1.4</pdfVersion>
<pdfPageCount>6</pdfPageCount>
<pdfPageSize>595.276 x 790.866 pts</pdfPageSize>
<refBibsNative>false</refBibsNative>
<abstractWordCount>187</abstractWordCount>
<abstractCharCount>1344</abstractCharCount>
<keywordCount>5</keywordCount>
</qualityIndicators>
<title>Refractory multisystem sarcoidosis responding to infliximab therapy</title>
<genre>
<json:string>review-article</json:string>
</genre>
<host>
<title>Clinical Rheumatology</title>
<language>
<json:string>unknown</json:string>
</language>
<publicationDate>2012</publicationDate>
<copyrightDate>2012</copyrightDate>
<issn>
<json:string>0770-3198</json:string>
</issn>
<eissn>
<json:string>1434-9949</json:string>
</eissn>
<journalId>
<json:string>10067</json:string>
</journalId>
<volume>31</volume>
<issue>6</issue>
<pages>
<first>1013</first>
<last>1018</last>
</pages>
<genre>
<json:string>journal</json:string>
</genre>
<subject>
<json:item>
<value>Rheumatology</value>
</json:item>
</subject>
</host>
<ark>
<json:string>ark:/67375/VQC-XQPFMTGL-4</json:string>
</ark>
<publicationDate>2012</publicationDate>
<copyrightDate>2012</copyrightDate>
<doi>
<json:string>10.1007/s10067-011-1933-9</json:string>
</doi>
<id>4303396DF0D0F3299EE4D5B86D8FEDA5DB53C7F9</id>
<score>1</score>
<fulltext>
<json:item>
<extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/ark:/67375/VQC-XQPFMTGL-4/fulltext.pdf</uri>
</json:item>
<json:item>
<extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/ark:/67375/VQC-XQPFMTGL-4/bundle.zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/VQC-XQPFMTGL-4/fulltext.tei">
<teiHeader>
<fileDesc>
<titleStmt>
<title level="a" type="main" xml:lang="en">Refractory multisystem sarcoidosis responding to infliximab therapy</title>
</titleStmt>
<publicationStmt>
<authority>ISTEX</authority>
<publisher scheme="https://scientific-publisher.data.istex.fr">Springer-Verlag</publisher>
<pubPlace>London</pubPlace>
<availability>
<licence>
<p>Clinical Rheumatology, 2012</p>
</licence>
<p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</p>
</availability>
<date>2011-12-12</date>
</publicationStmt>
<notesStmt>
<note type="review-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</note>
<note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note>
<note>Case Based Review</note>
</notesStmt>
<sourceDesc>
<biblStruct type="inbook">
<analytic>
<title level="a" type="main" xml:lang="en">Refractory multisystem sarcoidosis responding to infliximab therapy</title>
<author xml:id="author-0000">
<persName>
<forename type="first">Adam</forename>
<surname>Croft</surname>
</persName>
<affiliation>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</affiliation>
<affiliation>School of Infection and Immunity, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, B15 2TT, Birmingham, UK</affiliation>
</author>
<author xml:id="author-0001">
<persName>
<forename type="first">Deva</forename>
<surname>Situnayake</surname>
</persName>
<affiliation>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</affiliation>
</author>
<author xml:id="author-0002">
<persName>
<forename type="first">Omer</forename>
<surname>Khair</surname>
</persName>
<affiliation>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</affiliation>
</author>
<author xml:id="author-0003">
<persName>
<forename type="first">Gavin</forename>
<surname>Giovanni</surname>
</persName>
<affiliation>Queen Mary University of London, Centre for Neuroscience and Trauma, Blizard Institute, Barts and The London School of Medicine and Dentistry, 4 Newark Street, E1 2AT, London, UK</affiliation>
</author>
<author xml:id="author-0004">
<persName>
<forename type="first">David</forename>
<surname>Carruthers</surname>
</persName>
<affiliation>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</affiliation>
</author>
<author xml:id="author-0005">
<persName>
<forename type="first">Arul</forename>
<surname>Sivaguru</surname>
</persName>
<affiliation>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</affiliation>
</author>
<author xml:id="author-0006" corresp="yes">
<persName>
<forename type="first">Caroline</forename>
<surname>Gordon</surname>
</persName>
<email>p.c.gordon@bham.ac.uk</email>
<affiliation>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</affiliation>
<affiliation>School of Infection and Immunity, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, B15 2TT, Birmingham, UK</affiliation>
</author>
<idno type="istex">4303396DF0D0F3299EE4D5B86D8FEDA5DB53C7F9</idno>
<idno type="ark">ark:/67375/VQC-XQPFMTGL-4</idno>
<idno type="DOI">10.1007/s10067-011-1933-9</idno>
<idno type="article-id">1933</idno>
<idno type="article-id">s10067-011-1933-9</idno>
</analytic>
<monogr>
<title level="j">Clinical Rheumatology</title>
<title level="j" type="sub">Journal of the International League of Associations for Rheumatology</title>
<title level="j" type="abbrev">Clin Rheumatol</title>
<idno type="pISSN">0770-3198</idno>
<idno type="eISSN">1434-9949</idno>
<idno type="journal-ID">true</idno>
<idno type="issue-article-count">18</idno>
<idno type="volume-issue-count">12</idno>
<imprint>
<publisher>Springer-Verlag</publisher>
<pubPlace>London</pubPlace>
<date type="published" when="2012-06-01"></date>
<biblScope unit="volume">31</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="1013">1013</biblScope>
<biblScope unit="page" to="1018">1018</biblScope>
</imprint>
</monogr>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<creation>
<date>2011-12-12</date>
</creation>
<langUsage>
<language ident="en">en</language>
</langUsage>
<abstract xml:lang="en">
<p>Abstract: Chronic progressive multisystem granulomatous disease is seen in 10–30% of patients with sarcoidosis and can result in end organ damage. Corticosteroids are the mainstay of treatment with the addition of cytotoxic agents in severe cases. Some patients are refractory to such treatment and, therefore, management is a challenge. There is currently limited evidence for biological agents such as infliximab, a monoclonal anti-tumor necrosis factor-α antibody in the treatment of multisystem sarcoidosis. We report outcomes of three patients with extensive multisystem sarcoidosis refractory to conventional treatment and treated at our center. Clinical assessment and radiographic imaging were used to assess the response to infliximab treatment. Infliximab therapy induced clinical remission in all three patients, and this clinical response correlated with radiographic evidence of the resolution of granulomatous disease. Serum ACE level was reduced in all cases, and daily steroid dosage was reduced. We propose that infliximab can be an effective treatment in patients with multisystem complex sarcoidosis refractory to conventional drug therapy and can result in sustained clinical remission. Our experience supports the urgent need for randomized controlled clinical trials of anti-TNF therapy in refractory systemic sarcoidosis.</p>
</abstract>
<textClass xml:lang="en">
<keywords scheme="keyword">
<list>
<head>Keywords</head>
<item>
<term>Anti-TNF</term>
</item>
<item>
<term>Infliximab</term>
</item>
<item>
<term>Neurosarcoidosis</term>
</item>
<item>
<term>Refractory</term>
</item>
<item>
<term>Sarcoidosis</term>
</item>
</list>
</keywords>
</textClass>
<textClass>
<keywords scheme="Journal Subject">
<list>
<head>Medicine & Public Health</head>
<item>
<term>Rheumatology</term>
</item>
</list>
</keywords>
</textClass>
</profileDesc>
<revisionDesc>
<change when="2011-12-12">Created</change>
<change when="2012-06-01">Published</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item>
<extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/ark:/67375/VQC-XQPFMTGL-4/fulltext.txt</uri>
</json:item>
</fulltext>
<metadata>
<istex:metadataXml wicri:clean="corpus springer-journals not found" wicri:toSee="no header">
<istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration>
<istex:docType PUBLIC="-//Springer-Verlag//DTD A++ V2.4//EN" URI="http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd" name="istex:docType"></istex:docType>
<istex:document>
<Publisher>
<PublisherInfo>
<PublisherName>Springer-Verlag</PublisherName>
<PublisherLocation>London</PublisherLocation>
</PublisherInfo>
<Journal OutputMedium="All">
<JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered">
<JournalID>10067</JournalID>
<JournalPrintISSN>0770-3198</JournalPrintISSN>
<JournalElectronicISSN>1434-9949</JournalElectronicISSN>
<JournalTitle>Clinical Rheumatology</JournalTitle>
<JournalSubTitle>Journal of the International League of Associations for Rheumatology</JournalSubTitle>
<JournalAbbreviatedTitle>Clin Rheumatol</JournalAbbreviatedTitle>
<JournalSubjectGroup>
<JournalSubject Type="Primary">Medicine & Public Health</JournalSubject>
<JournalSubject Type="Secondary">Rheumatology</JournalSubject>
</JournalSubjectGroup>
</JournalInfo>
<Volume OutputMedium="All">
<VolumeInfo TocLevels="0" VolumeType="Regular">
<VolumeIDStart>31</VolumeIDStart>
<VolumeIDEnd>31</VolumeIDEnd>
<VolumeIssueCount>12</VolumeIssueCount>
</VolumeInfo>
<Issue IssueType="Regular" OutputMedium="All">
<IssueInfo IssueType="Regular" TocLevels="0">
<IssueIDStart>6</IssueIDStart>
<IssueIDEnd>6</IssueIDEnd>
<IssueArticleCount>18</IssueArticleCount>
<IssueHistory>
<OnlineDate>
<Year>2012</Year>
<Month>5</Month>
<Day>30</Day>
</OnlineDate>
<PrintDate>
<Year>2012</Year>
<Month>5</Month>
<Day>29</Day>
</PrintDate>
<CoverDate>
<Year>2012</Year>
<Month>6</Month>
</CoverDate>
<PricelistYear>2012</PricelistYear>
</IssueHistory>
<IssueCopyright>
<CopyrightHolderName>Clinical Rheumatology</CopyrightHolderName>
<CopyrightYear>2012</CopyrightYear>
</IssueCopyright>
</IssueInfo>
<Article ID="s10067-011-1933-9" OutputMedium="All">
<ArticleInfo ArticleType="ReviewPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0">
<ArticleID>1933</ArticleID>
<ArticleDOI>10.1007/s10067-011-1933-9</ArticleDOI>
<ArticleSequenceNumber>17</ArticleSequenceNumber>
<ArticleTitle Language="En">Refractory multisystem sarcoidosis responding to infliximab therapy</ArticleTitle>
<ArticleCategory>Case Based Review</ArticleCategory>
<ArticleFirstPage>1013</ArticleFirstPage>
<ArticleLastPage>1018</ArticleLastPage>
<ArticleHistory>
<RegistrationDate>
<Year>2011</Year>
<Month>12</Month>
<Day>23</Day>
</RegistrationDate>
<Received>
<Year>2011</Year>
<Month>12</Month>
<Day>12</Day>
</Received>
<Accepted>
<Year>2011</Year>
<Month>12</Month>
<Day>22</Day>
</Accepted>
<OnlineDate>
<Year>2012</Year>
<Month>1</Month>
<Day>17</Day>
</OnlineDate>
</ArticleHistory>
<ArticleCopyright>
<CopyrightHolderName>Clinical Rheumatology</CopyrightHolderName>
<CopyrightYear>2012</CopyrightYear>
</ArticleCopyright>
<ArticleGrants Type="Regular">
<MetadataGrant Grant="OpenAccess"></MetadataGrant>
<AbstractGrant Grant="OpenAccess"></AbstractGrant>
<BodyPDFGrant Grant="Restricted"></BodyPDFGrant>
<BodyHTMLGrant Grant="Restricted"></BodyHTMLGrant>
<BibliographyGrant Grant="Restricted"></BibliographyGrant>
<ESMGrant Grant="Restricted"></ESMGrant>
</ArticleGrants>
</ArticleInfo>
<ArticleHeader>
<AuthorGroup>
<Author AffiliationIDS="Aff1 Aff2">
<AuthorName DisplayOrder="Western">
<GivenName>Adam</GivenName>
<GivenName>P.</GivenName>
<FamilyName>Croft</FamilyName>
</AuthorName>
</Author>
<Author AffiliationIDS="Aff1">
<AuthorName DisplayOrder="Western">
<GivenName>Deva</GivenName>
<FamilyName>Situnayake</FamilyName>
</AuthorName>
</Author>
<Author AffiliationIDS="Aff1">
<AuthorName DisplayOrder="Western">
<GivenName>Omer</GivenName>
<FamilyName>Khair</FamilyName>
</AuthorName>
</Author>
<Author AffiliationIDS="Aff3">
<AuthorName DisplayOrder="Western">
<GivenName>Gavin</GivenName>
<FamilyName>Giovanni</FamilyName>
</AuthorName>
</Author>
<Author AffiliationIDS="Aff1">
<AuthorName DisplayOrder="Western">
<GivenName>David</GivenName>
<FamilyName>Carruthers</FamilyName>
</AuthorName>
</Author>
<Author AffiliationIDS="Aff1">
<AuthorName DisplayOrder="Western">
<GivenName>Arul</GivenName>
<FamilyName>Sivaguru</FamilyName>
</AuthorName>
</Author>
<Author AffiliationIDS="Aff1 Aff2" CorrespondingAffiliationID="Aff2">
<AuthorName DisplayOrder="Western">
<GivenName>Caroline</GivenName>
<FamilyName>Gordon</FamilyName>
</AuthorName>
<Contact>
<Email>p.c.gordon@bham.ac.uk</Email>
</Contact>
</Author>
<Affiliation ID="Aff1">
<OrgDivision>Sandwell and West Birmingham Hospitals NHS Trust</OrgDivision>
<OrgName>City Hospital</OrgName>
<OrgAddress>
<Street>Dudley Road</Street>
<City>Birmingham</City>
<Postcode>B18 7QH</Postcode>
<Country Code="GB">UK</Country>
</OrgAddress>
</Affiliation>
<Affiliation ID="Aff2">
<OrgDivision>School of Infection and Immunity, College of Medical and Dental Sciences</OrgDivision>
<OrgName>University of Birmingham</OrgName>
<OrgAddress>
<Street>Edgbaston</Street>
<City>Birmingham</City>
<Postcode>B15 2TT</Postcode>
<Country Code="GB">UK</Country>
</OrgAddress>
</Affiliation>
<Affiliation ID="Aff3">
<OrgName>Queen Mary University of London, Centre for Neuroscience and Trauma, Blizard Institute, Barts and The London School of Medicine and Dentistry</OrgName>
<OrgAddress>
<Street>4 Newark Street</Street>
<City>London</City>
<Postcode>E1 2AT</Postcode>
<Country Code="GB">UK</Country>
</OrgAddress>
</Affiliation>
</AuthorGroup>
<Abstract ID="Abs1" Language="En" OutputMedium="All">
<Heading>Abstract</Heading>
<Para>Chronic progressive multisystem granulomatous disease is seen in 10–30% of patients with sarcoidosis and can result in end organ damage. Corticosteroids are the mainstay of treatment with the addition of cytotoxic agents in severe cases. Some patients are refractory to such treatment and, therefore, management is a challenge. There is currently limited evidence for biological agents such as infliximab, a monoclonal anti-tumor necrosis factor-α antibody in the treatment of multisystem sarcoidosis. We report outcomes of three patients with extensive multisystem sarcoidosis refractory to conventional treatment and treated at our center. Clinical assessment and radiographic imaging were used to assess the response to infliximab treatment. Infliximab therapy induced clinical remission in all three patients, and this clinical response correlated with radiographic evidence of the resolution of granulomatous disease. Serum ACE level was reduced in all cases, and daily steroid dosage was reduced. We propose that infliximab can be an effective treatment in patients with multisystem complex sarcoidosis refractory to conventional drug therapy and can result in sustained clinical remission. Our experience supports the urgent need for randomized controlled clinical trials of anti-TNF therapy in refractory systemic sarcoidosis.</Para>
</Abstract>
<KeywordGroup Language="En" OutputMedium="All">
<Heading>Keywords</Heading>
<Keyword>Anti-TNF</Keyword>
<Keyword>Infliximab</Keyword>
<Keyword>Neurosarcoidosis</Keyword>
<Keyword>Refractory</Keyword>
<Keyword>Sarcoidosis</Keyword>
</KeywordGroup>
</ArticleHeader>
<NoBody></NoBody>
</Article>
</Issue>
</Volume>
</Journal>
</Publisher>
</istex:document>
</istex:metadataXml>
<mods version="3.6">
<titleInfo lang="en">
<title>Refractory multisystem sarcoidosis responding to infliximab therapy</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA">
<title>Refractory multisystem sarcoidosis responding to infliximab therapy</title>
</titleInfo>
<name type="personal">
<namePart type="given">Adam</namePart>
<namePart type="given">P.</namePart>
<namePart type="family">Croft</namePart>
<affiliation>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</affiliation>
<affiliation>School of Infection and Immunity, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, B15 2TT, Birmingham, UK</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Deva</namePart>
<namePart type="family">Situnayake</namePart>
<affiliation>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Omer</namePart>
<namePart type="family">Khair</namePart>
<affiliation>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Gavin</namePart>
<namePart type="family">Giovanni</namePart>
<affiliation>Queen Mary University of London, Centre for Neuroscience and Trauma, Blizard Institute, Barts and The London School of Medicine and Dentistry, 4 Newark Street, E1 2AT, London, UK</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">David</namePart>
<namePart type="family">Carruthers</namePart>
<affiliation>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Arul</namePart>
<namePart type="family">Sivaguru</namePart>
<affiliation>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal" displayLabel="corresp">
<namePart type="given">Caroline</namePart>
<namePart type="family">Gordon</namePart>
<affiliation>Sandwell and West Birmingham Hospitals NHS Trust, City Hospital, Dudley Road, B18 7QH, Birmingham, UK</affiliation>
<affiliation>School of Infection and Immunity, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, B15 2TT, Birmingham, UK</affiliation>
<affiliation>E-mail: p.c.gordon@bham.ac.uk</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="review-article" displayLabel="ReviewPaper" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</genre>
<originInfo>
<publisher>Springer-Verlag</publisher>
<place>
<placeTerm type="text">London</placeTerm>
</place>
<dateCreated encoding="w3cdtf">2011-12-12</dateCreated>
<dateIssued encoding="w3cdtf">2012-06-01</dateIssued>
<copyrightDate encoding="w3cdtf">2012</copyrightDate>
</originInfo>
<language>
<languageTerm type="code" authority="rfc3066">en</languageTerm>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<abstract lang="en">Abstract: Chronic progressive multisystem granulomatous disease is seen in 10–30% of patients with sarcoidosis and can result in end organ damage. Corticosteroids are the mainstay of treatment with the addition of cytotoxic agents in severe cases. Some patients are refractory to such treatment and, therefore, management is a challenge. There is currently limited evidence for biological agents such as infliximab, a monoclonal anti-tumor necrosis factor-α antibody in the treatment of multisystem sarcoidosis. We report outcomes of three patients with extensive multisystem sarcoidosis refractory to conventional treatment and treated at our center. Clinical assessment and radiographic imaging were used to assess the response to infliximab treatment. Infliximab therapy induced clinical remission in all three patients, and this clinical response correlated with radiographic evidence of the resolution of granulomatous disease. Serum ACE level was reduced in all cases, and daily steroid dosage was reduced. We propose that infliximab can be an effective treatment in patients with multisystem complex sarcoidosis refractory to conventional drug therapy and can result in sustained clinical remission. Our experience supports the urgent need for randomized controlled clinical trials of anti-TNF therapy in refractory systemic sarcoidosis.</abstract>
<note>Case Based Review</note>
<subject lang="en">
<genre>Keywords</genre>
<topic>Anti-TNF</topic>
<topic>Infliximab</topic>
<topic>Neurosarcoidosis</topic>
<topic>Refractory</topic>
<topic>Sarcoidosis</topic>
</subject>
<relatedItem type="host">
<titleInfo>
<title>Clinical Rheumatology</title>
<subTitle>Journal of the International League of Associations for Rheumatology</subTitle>
</titleInfo>
<titleInfo type="abbreviated">
<title>Clin Rheumatol</title>
</titleInfo>
<genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre>
<originInfo>
<publisher>Springer</publisher>
<dateIssued encoding="w3cdtf">2012-05-30</dateIssued>
<copyrightDate encoding="w3cdtf">2012</copyrightDate>
</originInfo>
<subject>
<genre>Medicine & Public Health</genre>
<topic>Rheumatology</topic>
</subject>
<identifier type="ISSN">0770-3198</identifier>
<identifier type="eISSN">1434-9949</identifier>
<identifier type="JournalID">10067</identifier>
<identifier type="IssueArticleCount">18</identifier>
<identifier type="VolumeIssueCount">12</identifier>
<part>
<date>2012</date>
<detail type="volume">
<number>31</number>
<caption>vol.</caption>
</detail>
<detail type="issue">
<number>6</number>
<caption>no.</caption>
</detail>
<extent unit="pages">
<start>1013</start>
<end>1018</end>
</extent>
</part>
<recordInfo>
<recordOrigin>Clinical Rheumatology, 2012</recordOrigin>
</recordInfo>
</relatedItem>
<identifier type="istex">4303396DF0D0F3299EE4D5B86D8FEDA5DB53C7F9</identifier>
<identifier type="ark">ark:/67375/VQC-XQPFMTGL-4</identifier>
<identifier type="DOI">10.1007/s10067-011-1933-9</identifier>
<identifier type="ArticleID">1933</identifier>
<identifier type="ArticleID">s10067-011-1933-9</identifier>
<accessCondition type="use and reproduction" contentType="copyright">Clinical Rheumatology, 2012</accessCondition>
<recordInfo>
<recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</recordContentSource>
<recordOrigin>Clinical Rheumatology, 2012</recordOrigin>
</recordInfo>
</mods>
<json:item>
<extension>json</extension>
<original>false</original>
<mimetype>application/json</mimetype>
<uri>https://api.istex.fr/ark:/67375/VQC-XQPFMTGL-4/record.json</uri>
</json:item>
</metadata>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F35 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001F35 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:4303396DF0D0F3299EE4D5B86D8FEDA5DB53C7F9
   |texte=   Refractory multisystem sarcoidosis responding to infliximab therapy
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021